scorecardresearch
Tuesday, August 26, 2025
TopicJohnson and Johnson

Topic: Johnson and Johnson

Rs 1 crore damages for ‘blatant infringement’: Johnson & Johnson’s big win in court against ORS copycats

New Delhi: The Delhi High Court has awarded damages of Rs 1.2 crore to multinational pharma company Johnson & Johnson in an infringement case...

Johnson & Johnson granted Rs 3.34 crore in damages by HC, what was the counterfeit products case

Offender was found to be a person, who ran a company by the name of Medserve. All seized counterfeit products can be destroyed by the healthcare giant, says HC.

Two doses of J&J’s vaccine slashes Omicron hospital stays in South Africa by up to 85%

The results are a welcome bit of news amid the explosive rise of Omicron cases and evidence that the strain can evade the protection that normally stems from vaccination.

Johnson & Johnson vaccine doesn’t provide antibody protection against Omicron, lab study finds

The J&J vaccine appears to provide some defense against Omicron, perhaps via other means such as stimulation of immune cells, according to a South African virologist.

US scientists suggest link between J&J vaccine and brain blood clots, but warn against panic

Researchers noted that the risk of blood clots should be considered in context of the vaccine’s efficacy, saying it is effective in offering protection from severe Covid-19.

Moderna, J&J boosters get US CDC’s backing, paving way for next shots

The CDC said eligible people may choose a different booster from the vaccine they originally received, granting more flexibility to patients and doctors.

US FDA clears Moderna, J&J booster shots, allows ‘mix and match’ of Covid vaccines

The Centers for Disease Control & Prevention will consult an expert panel later this week before finalising official recommendations for who should get boosters and when.

Johnson & Johnson seeks nod to conduct vaccine trails for 12-17 age group in India

Earlier in August, the US pharma giant Johnson & Johnson was given emergency use approval in India for its single-dose Covid-19 vaccine.

No clarity on India launch of single-dose J&J Covid jab as talks focus on indemnity hurdle

US pharmaceutical companies like Moderna, Pfizer and Johnson & Johnson have asked for indemnity against legal liability but the Government of India has not been inclined to give it.

J&J Covid vaccine gets emergency use nod in India. Here’s how the single-dose jab works

J&J became the fifth vaccine to get an emergency nod in the country, after Covishield, Covaxin, Sputnik V and Moderna.

On Camera

India will absorb Trump tariff impact due to its Achilles’ heel

Like China, India remains a big domestic market, which will continue to attract investment, but the US tariffs will make India unattractive for future investments.

New insolvency frameworks to shorter timelines, how 2025 amendment bill proposes to transform IBC

New bill aims to fix key issues with IBC 2016, including delays & patchy implementation, and protect creditors, with window for genuine promoters to retain control of their companies.

‘Peace without power Utopian, lessons from Op Sindoor being implemented’—CDS inaugurates Ran Samvad

India’s 1st tri-service seminar, on the lines of Shangri-La Dialogue, kicks off in Mhow, with top military officers & defence attaches from several countries in attendance.

That Oval Office picture for ages deserves closer Indian reading, with a geopolitical lens

Putin sees this as a victory. Europeans have decided to deal with Trump on his terms for the sake of the larger Western alliance. We look at the lessons for us in India.